in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
🤔 Screening for albuminuria is cost-effective
Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis (Cusick, Annals Int Med 2023)
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
